Essential answer
This research record is a discovery and appraisal pathway. Inclusion helps readers find evidence but does not certify that every result is correct, current or applicable.
Complete public explanation
A source-linked hiv r&d record covering open research questions, evidence status, limitations, implementation and related research.
Use the information with its source date, population and jurisdiction. A general explanation cannot determine an individual’s diagnosis, eligibility, regimen or legal obligations.
Key considerations
- Open the original publication or dataset.
- Check design, population, outcomes, funding and conflicts.
- Look for protocol registration, corrections and later evidence.
- Separate research findings from clinical recommendations.
Research and evidence questions
Professional and academic evidence
Professional interpretation of open research questions adds study design, population, comparator, outcomes, statistical methods, limitations, conflicts, guideline adoption, geographic applicability, replication and integrity status.
| Field | What the Center displays |
|---|---|
| Meaning and scope | Definition, mechanism, intended use and what should not be inferred. |
| Population and jurisdiction | Age, sex and gender, geography, HIV subtype, clinical context and issuing authority. |
| Outcome | Clinical, virologic, diagnostic, public-health or implementation outcome and follow-up. |
| Provenance | Original source, identifier, version, funding, conflicts, access date and review. |
| Integrity | Protocol changes, corrections, expressions of concern, retractions and later evidence. |
Active research and development directions
Evidence reviewed 18 Aug 2026The portfolio separates established tools, clinical research, early human studies, preclinical science and implementation research. A promising mechanism is never presented as a cure.
Lenacapavir has moved long-acting HIV prevention from a trial concept into guideline and regulatory implementation. The research question is now as much about equitable delivery, testing and persistence as biological efficacy.
Injectable and extended-duration antiretroviral platforms aim to reduce dosing burden while maintaining suppression. Current research explores wider populations, longer intervals, oral weekly regimens and combinations with new mechanisms.
Rather than asking one immunogen to produce mature broadly neutralizing antibodies, germline-targeting programmes try to activate rare precursor B cells and guide their maturation through a planned sequence of immunogens.
Broadly neutralizing antibodies can directly block susceptible HIV variants and recruit immune functions. Combinations are designed to widen coverage and reduce escape, with studies testing prevention, treatment support and remission after pausing ART.
Therapeutic vaccines aim to strengthen or redirect immune control in people who already have HIV. The leading strategy is combination treatment rather than vaccination alone.
The ‘shock and kill’ family of strategies tries to expose latent proviruses and then remove infected cells. Research has increasingly shifted toward combination designs because latency reversal alone has not reliably reduced the intact reservoir.
Block-and-lock strategies seek to place persistent HIV into a deeper, durable transcriptionally silent state so that rebound remains suppressed without continuous ART, even if every provirus is not removed.
Gene-editing programmes aim either to cut conserved HIV sequences from infected cells or make target cells resistant to infection. The first challenge is safe delivery to enough relevant cells and tissues.
Cell therapies attempt to provide persistent immune effectors that recognize conserved HIV targets, resist exhaustion or deliver antiviral molecules. Designs include expanded HIV-specific T cells, engineered receptors and NK-cell approaches.
Rare cures after donor stem-cell transplantation prove that durable HIV remission is biologically possible, but transplantation risk makes that route inappropriate for routine HIV care. Research therefore explores safer engineered autologous cells and multilayered resistance.
Cure research depends on measuring a rare, diverse and anatomically distributed reservoir. No single assay captures intactness, inducibility, integration site, clonality, transcription and rebound competence at once.
A scientifically successful intervention has limited public-health value if it cannot reach the populations and regions most affected by HIV. Equity research must begin during product design, not after approval.